Oral salbutamol decreases IL-12 in patients with secondary progressive multiple sclerosis
- 1 July 2001
- journal article
- Published by Elsevier in Journal of Neuroimmunology
- Vol. 117 (1-2) , 156-165
- https://doi.org/10.1016/s0165-5728(01)00322-8
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Interferon β in multiple sclerosis: is IL-12 suppression the key?Immunology Today, 2000
- Differential regulation of IFN‐γ, IL‐10 and inducible nitric oxide synthase in human T cells by cyclic AMP‐dependent signal transduction pathwayImmunology, 1997
- Differential modulation of B7‐1 and B7‐2 isoform expression on human monocytes by cytokines which influence the development of T helper cell phenotypeEuropean Journal of Immunology, 1996
- IL-12-Deficient Mice Are Defective in IFNγ Production and Type 1 Cytokine ResponsesImmunity, 1996
- The role of IL-12 in the induction of organ-specific autoimmune diseasesImmunology Today, 1995
- Interleukin-12: A Proinflammatory Cytokine with Immunoregulatory Functions that Bridge Innate Resistance and Antigen-Specific Adaptive ImmunityAnnual Review of Immunology, 1995
- Up-regulation of monocytic IL-10 by tumor necrosis factor-α and cAMP elevating drugsInternational Immunology, 1995
- β-Adrenergic agonists suppress chronic/relapsing experimental allergic encephalomyelitis (CREAE) in Lewis ratsJournal of Neuroimmunology, 1995
- Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12.The Journal of Experimental Medicine, 1995
- EXACERBATIONS OF MULTIPLE SCLEROSIS IN PATIENTS TREATED WITH GAMMA INTERFERONPublished by Elsevier ,1987